Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 June;49(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 June;49(2):205-14

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 June;49(2):205-14

SINGLE PHOTON EMISSION TOMOGRAPHY 

 REVIEW ARTICLES

SPET in psychopharmacolgy

Moresco R. M., Fazio F.

IBFM-CNR, Scientific Institute San Raffaele University of Milan-Bicocca, Milan, Italy

Positron emission tomography (PET) and single photon emission tomography (SPET) permit the in vivo assesment of human biological processes with methods originally developed for preclinical studies. This opportunity is of primary interest in biological psychiatry and in psychoactive drugs development. Most of research efforts have focused on the use of PET field, and several biological finding on central nervous system (CNS) diseases have been published. Despite methodological limitations, the feasibility and usefulness of SPET for research, including full quantification, kinetic modeling and tracer validation, has been clearly demonstrated. The aim of this paper is to review advantages, limitations and results of SPET in psychopharmacology.

language: English


FULL TEXT  REPRINTS

top of page